Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 57 of 292 for:    ASPIRIN AND clopidogrel AND dual

Comparison One vs Six Months of Dual Antiplatelet Therapy After Implanted Firehawk TM Stent in High Bleeding Risk Patients With Coronary Artery Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03287167
Recruitment Status : Recruiting
First Posted : September 19, 2017
Last Update Posted : June 17, 2019
Sponsor:
Information provided by (Responsible Party):
Shanghai MicroPort Medical (Group) Co., Ltd.

Brief Summary:
This study is to assess the clinical non-inferiority of 1 month (short-term) vs 6 months (long-term) of dual anti-platelet therapy in patients undergoing percutaneous intervention implanted sirolimus -eluting stent with abluminal grooves containing a biodegradable polymer in High Bleeding Risk patients with coronary artery disease.

Condition or disease Intervention/treatment Phase
Coronary Disease Drug Eluting Stent Percutaneous Coronary Intervention Dual Antiplatelet Therapy Drug: 1 month DAPT Drug: 6 months DAPT Phase 4

Detailed Description:
This is a prospective, double -blind,multi-center,randomized controlled trial. Approximately 1,720 subjects in high bleeding risk with coronary artery disease will be enrolled in no more than 40 research centers in China. All participants met the inclusion criteria will be 1:1 randomized to 1 month or 6months of DAPT after implanting Firehawk™ coronary stent. Clinical follow-up will be carried out at 30 days, 6 months, 12 months, 2 years after index procedure.The primary study endpoint is Net Adverse Clinical and Cerebral Events (NACCE), a composite of all-cause death, myocardial infarction (MI), cerebral vascular accident (CVA) and major bleeding ([BARC] definition) at 12 months. Subjects that complete of 12 months follow-up will be regarded as having completed the primary endpoint. The secondary study endpoints contain cost-effectiveness at 12 months, ARC defined stent thrombosis (ST) ; NACCE ;major adverse cardiovascular events (MACE),major adverse cardiovascular and cerebral events (MACCE),target lesion revascularization (TLR),target vessel failure(TVF) , major bleeding at 30 days,6,12 and 24 months of follow-up.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1720 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Prospective, Double -Blind ,Multi-center,Randomized Controled Trial of Comparison One vs Six Months of Dual Antiplatelet Therapy After Implanted Sirolimus- Eluting Stent With Abluminal Grooves Containing A Biodegradable Polymer (FirehawkTM Stent ) in High Bleeding Risk Patients With Coronary Artery Disease
Actual Study Start Date : June 1, 2019
Estimated Primary Completion Date : July 2021
Estimated Study Completion Date : July 30, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 1 month DAPT intervention
After implantation of Firehawk coronary stents, 860 subjects in intervention group will be given dual anti-platelet therapy (DAPT) including aspirin and clopidogrel for 1 month, then will be given aspirin and placebo for next 5 months.
Drug: 1 month DAPT
Subjects will continue DAPT with clopidogrel and Aspirin (ASA) up to 1 month, after which patients will be given ASA and placebo in next 5 months and then continue on monotherapy with ASA only, unless contraindications for ASA emerge.

Active Comparator: 6 months DAPT intervention
After implantation of Firehawk coronary stents, 860 subjects in control group will be given dual anti-platelet therapy (DAPT) including aspirin and clopidogrel for 6 months.
Drug: 6 months DAPT
Subjects will continue DAPT with clopidogrel and Aspirin (ASA) up to 6 months, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.




Primary Outcome Measures :
  1. Net Adverse Clinical and Cerebral Events (NACCE) [ Time Frame: At 12 months after index procedure ]
    A composite of all-cause death, MI, cerebral vascular accident (CVA) and major bleeding at 18 months


Secondary Outcome Measures :
  1. Target Vessel Revascularization (TVR) [ Time Frame: In hospital and at 30 days,6, 12 and 24 months after index procedure ]
  2. Target lesion Revascularization (TLR) [ Time Frame: In hospital and at 30 days,6, 12 and 24 months after index procedure ]
  3. Target Vessel Failure (TVF) [ Time Frame: In hospital and at 30 days,6, 12 and 24 months after index procedure ]
  4. Target Lesion Failure (TLF) [ Time Frame: In hospital and at 30 days,6, 12 and 24 months after index procedure ]
  5. Stent Thrombosis (per ARC definition) [ Time Frame: In hospital and at 30 days,6, 12 and 24 months after index procedure ]
    the definite and probable stent thrombosis

  6. Major Adverse Cardiac and Cerebral Events(MACCE) [ Time Frame: In hospital and at 30 days,6, 12 and 24 months after index procedure ]
  7. Net Adverse Clinical and Cerebral Events (NACCE) [ Time Frame: In hospital and at 30 days,6, 12 and 24 months after index procedure ]
  8. Myocardial Infarction (MI,including Q-wave MI and non Q-wave MI) [ Time Frame: In hospital and at 30 days,6, 12 and 24 months after index procedure ]
  9. Death (All cause, Cardiac, Non-cardiac) [ Time Frame: In hospital and at 30 days,6, 12 and 24 months after index procedure ]
  10. Cardiac Death [ Time Frame: In hospital and at 30 days,6, 12 and 24 months after index procedure ]
  11. Non-Cardiac Death [ Time Frame: In hospital and at 30 days,6, 12 and 24 months after index procedure ]
  12. Major Bleeding [ Time Frame: In hospital and at 30 days,6, 12 and 24 months after index procedure ]
    [BARC] definition


Other Outcome Measures:
  1. Cost-Effectiveness Ratio (CER) [ Time Frame: At 12 months after index procedure ]
    CER = [total medical care costs of anti-platelet therapy] / [number of participants without net adverse clinical and cerebral events (NACCE)]



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

General Inclusion Criteria:

  • Age ≥ 18 years;
  • Subjects (or legal guardians) understand the testing requirements and procedures, and provide written informed consent;
  • Subjects could undergo percutaneous coronary intervention (PCI);
  • Subjects have symptomatic coronary artery disease or have confirmed asymptomatic ischemia;
  • Subjects are eligible candidates for coronary artery bypass graft surgery (CABG);
  • Left ventricular ejection fraction (LVEF) within 60 days ≥ 30%;
  • Subjects were willing to accept the trial plan calls for all subsequent evaluations;
  • Subjects can endure 6 months dual anti-platelet therapy, and met one or more criteria as the following:

    1.Age ≥ 75years; 2.Subjects with hemoglobin<10g/dL, or subjects received transfusion therapy 4 weeks ago; 3.Subjects with renal insufficiency (eGFR < 60 ml / min); 4. Subjects with HAS-BLED score ≥3.0; 5.Femal patients with acute cononary syndrome; 6.BMI < 18.5 Kg/M2; 7.Subjects with congestive heart failure and with LVEF30%-50%; 8.Subjects had a history of hospitalization due to bleeding; 9.Subjects with thrombocytopenia (platelet < 100,000 / mm3); 10.Subjects had a histroy of intracranial hemorrhage; 11.Subjects had a histroy of intracranial ischemia stroke in 6 months; 12.Subjects plan to receive non-steroidal anti-inflammatory or steroid treatment for more than 30 days after the baseline PCI; 14.Subjects were expected to receive additional treatment after PCI and cannot undergo long-term DAPT therapy; 15.Subjects had a history of stomach ulcers or active ulcers.

Angiographic Inclusion Criteria

  • Target lesions must be new and have a visually estimated reference diameter ≥2.25 mm and ≤4.0 mm in autologous coronary artery;
  • Target lesions must be moderate-severe calcification;
  • No limitations in target lesion length and number, and the number of implanted stents is less than 4;
  • ALL target lesion must be able to successfully expand and implant Firehawk™ stent.

Clinical Exclusion Criteria:

  • Subjects recently suffer from MI (within 4 week) and ECG changes/clinical symptoms consistent with AMI, or accompanied with increased cardiac biomarkers (CK-MB, CK, TNT or TNI) and at least one of the following :

    1. CK-MB> 3ULN, regardless of the value of total CK;
    2. If CK-MB or CK was not detected, but cTN> 1ULN, and at least one of the following:

      1. Ischemic symptoms and ECG changes of new ischemia;
      2. Development of pathologic Q waves in the ECG;
      3. Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
  • Subject had Re-MI before randomized;
  • Subject with hemodynamic instability (Killip class IV);
  • Subjects were detected ventricular aneurysm greater than 3.0*2.0cm or intraventricular thrombosis by cardiac ultrasonography in 30 days;
  • Subjects with Life-threatening arrhythmias;
  • Subjects were expected to receive oral anticoagulation therapy after the baseline PCI;
  • Subjects cannot endure dual anti-platelet therapy for 1 month;
  • Subjects with mechanical complications after myocardial infarction;
  • Subjects had an organ transplant or are waiting for an organ transplant;
  • Subjects are receiving chemotherapy or will receive a chemotherapy within 30 days after PCI;
  • Subjects with abnormal counts of white blood cell (WBC);
  • Subjects with verified or suspected acute liver disease, including lab results of acute liver disease;
  • Subjects had permanent neurological diseases in the past 6 months;
  • Subjects had any PCI (such as balloon angioplasty, stent, cutting balloon) treatment in target vessels within 12 months prior to baseline;
  • Non-target vessel had been implanted non-research stent 5 months ago before the baselin PCI.
  • Subjects plan to undergo PCI or CABG within 1 year after the baseline PCI;
  • Subjects have any coronary endovascular brachytherapy treatment previously;
  • Subjects associated with drugs allergy (such as sirolimus, or structure-related compounds fluorinated polymers, thiophenepyridine or aspirin);
  • Subjects are suffering from other serious illness (such as cancer, congestive heart failure), which may cause drop in life expectancy to less than 12 months;
  • Subjects are currently abusing drugs (such as alcohol, cocaine, heroin, etc);
  • Subject plan to undergo any operations that may lead to confuse with the programme;
  • Subjects were participating in another study of drug or medical device which did not meet its primary endpoint;
  • Subjects plan to pregnant within 12 months after baseline;
  • Subjects are pregnant or breastfeeding women.

Angiographic Exclusion Criteria (visual estimate):

  • Target lesions with the following criteria: left main, saphenous vein grafts or arterial grafts, via saphenous vein grafts or arterial graft, more than 4 stents have been implanted and in-stent sestenosis;
  • Subjects with unprotected left main coronary artery disease (diameter stenosis >50%);
  • Subjects have a protected left main coronary artery disease (diameter stenosis> 50% and left coronary artery bypass surgery), as well as target lesions located in the LAD and LCX;
  • Subjects with other lesions of clinical significance, may be need intervention within 12 months after baseline.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03287167


Contacts
Layout table for location contacts
Contact: Ming Zheng, MD (86)(21)38954600-6229 mzheng@microport.com

Locations
Layout table for location information
China, Liaoning
The General Hospital of Shenyang Military Recruiting
Shenyang, Liaoning, China
Contact: Yalin Han, MD         
Sponsors and Collaborators
Shanghai MicroPort Medical (Group) Co., Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Yaling Han, MD The General Hospital of Shenyang Military

Layout table for additonal information
Responsible Party: Shanghai MicroPort Medical (Group) Co., Ltd.
ClinicalTrials.gov Identifier: NCT03287167     History of Changes
Other Study ID Numbers: TARGET SAFE
First Posted: September 19, 2017    Key Record Dates
Last Update Posted: June 17, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Aspirin
Clopidogrel
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Antipyretics
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents